×
SIGN UP FOR OUR MONTHLY NEWSLETTER

Think beyond compensation to benefits that can help you avoid burnout

New doctors are more likely to work for employers rather than for themselves. As we previously reported, 2016 marked the first year in which less than half of practicing physicians (just over 47 percent) owned their own practice. Nearly a third of doctors (32.8 percent) worked for hospital-owned practices or were employed directly by a hospital in 2016, according to the most recent American Medical Association (AMA) data. That number is expected to increase, since millennial doctors prefer careers as employees rather than as owners.Read More

The program that promised to reduce doctors’ student debt is falling short

The median cost of attending a four-year public medical school is more than $240,000. Private medical school fees can exceed $340,000, according to the Association of American Medical Colleges (AAMC). Most medical students rely heavily on financial aid to fund their education. The median education debt for new med school grads is $180,000, with 14 percent of graduates starting their residency owing $300,000 or more.Read More

There’s no clear-cut answer, but here are the main pros and cons to each career path

Health care experts have been predicting the end of independent practices for years now. And their numbers have continued to drop—a report from the American Medical Association showed that the percentage of doctors with an ownership stake in their practice declined to 47 percent in 2016. This is down from 53 percent in 2012, reported Medical Economics, which named “Remaining independent in a time of value-based care initiatives” as one of the top 10 challenges facing physicians in 2018. Read More

FDA approves new treatment that restores vision in patients with congenital blindness

In December, the FDA made history by approving a gene therapy for a rare inherited eye disease that causes blindness. This is the first gene therapy to be cleared in the U.S. for treatment of the eye or any inherited disease. And it’s only the third gene therapy approved for use in the U.S.; the other two therapies to gain approval earlier in 2017 treat blood cancers.Read More